77 related articles for article (PubMed ID: 26092169)
21. Binding of topotecan to a nicked DNA oligomer in solution.
Bocian W; Kawecki R; Bednarek E; Sitkowski J; Williamson MP; Hansen PE; Kozerski L
Chemistry; 2008; 14(9):2788-94. PubMed ID: 18214879
[TBL] [Abstract][Full Text] [Related]
22. Electrochemical investigation of the interaction between topotecan and DNA at disposable graphite electrodes.
Congur G; Erdem A; Mese F
Bioelectrochemistry; 2015 Apr; 102():21-8. PubMed ID: 25461757
[TBL] [Abstract][Full Text] [Related]
23. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
24. DOSY NMR and MALDI-TOF evidence of covalent binding the DNA duplex by trimethylammonium salts of topotecan upon near UV irradiation.
Naumczuk B; Hyz K; Kawęcki R; Bocian W; Bednarek E; Sitkowski J; Wielgus E; Kozerski L
Magn Reson Chem; 2015 Aug; 53(8):565-71. PubMed ID: 26017759
[TBL] [Abstract][Full Text] [Related]
25. Structural photodynamic behavior of topotecan, a potent anticancer drug, in aqueous solutions at different pHs.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jul; 116(28):8182-90. PubMed ID: 22712701
[TBL] [Abstract][Full Text] [Related]
26. Affinity of anticancer drug, daunomycin, to core histones in solution: comparison of free and cross-linked proteins.
Rabbani A; Abdosamadi S; Sari-Saraf N
Acta Pharmacol Sin; 2007 May; 28(5):731-7. PubMed ID: 17439730
[TBL] [Abstract][Full Text] [Related]
27. Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA.
Top M; Er O; Congur G; Erdem A; Lambrecht FY
Talanta; 2016 Nov; 160():157-163. PubMed ID: 27591600
[TBL] [Abstract][Full Text] [Related]
28. The effect of vinca alkaloid anticancer drug, vinorelbine, on chromatin and histone proteins in solution.
Rabbani-Chadegani A; Chamani E; Hajihassan Z
Eur J Pharmacol; 2009 Jun; 613(1-3):34-8. PubMed ID: 19394329
[TBL] [Abstract][Full Text] [Related]
29. [Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan].
strel'tsov SA; Mikheĭkin AL; Nechipurenko IuD
Mol Biol (Mosk); 2001; 35(3):442-50. PubMed ID: 11443926
[TBL] [Abstract][Full Text] [Related]
30. Topotecan-loaded mesoporous silica nanoparticles for reversing multi-drug resistance by synergetic chemoradiotherapy.
Shen B; Zhao K; Ma S; Yuan D; Bai Y
Chem Asian J; 2015 Feb; 10(2):344-8. PubMed ID: 25413970
[TBL] [Abstract][Full Text] [Related]
31. Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution.
Hajihassan Z; Rabbani-Chadegani A
Int J Biol Macromol; 2011 Jan; 48(1):87-92. PubMed ID: 20943200
[TBL] [Abstract][Full Text] [Related]
32. [Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].
Strel'tsov SA; Grokhovskiĭ SL; Kudelina IA; Oleĭnikov VA; Zhuze AL
Mol Biol (Mosk); 2001; 35(3):432-41. PubMed ID: 11443925
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a liquid chromatography-tandem mass spectrometry method for topotecan determination in beagle dog plasma and its application in a bioequivalence study.
Ye L; Shi J; Wan S; Yang X; Wang Y; Zhang J; Zheng D; Liu Z
Biomed Chromatogr; 2013 Nov; 27(11):1532-9. PubMed ID: 23788247
[TBL] [Abstract][Full Text] [Related]
34. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage.
Tomicic MT; Christmann M; Kaina B
J Pharmacol Exp Ther; 2010 Jan; 332(1):316-25. PubMed ID: 19812371
[TBL] [Abstract][Full Text] [Related]
35. Topotecan dynamics, tautomerism and reactivity--1H/13C NMR and ESI MS study.
Hyz K; Kawecki R; Bednarek E; Bocian W; Sitkowski J; Kozerski L
Magn Reson Chem; 2010 Aug; 48(8):575-84. PubMed ID: 20623719
[TBL] [Abstract][Full Text] [Related]
36. [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme].
Grokhovskiĭ SL; Strel'tsov SA; Zhuze AL
Mol Biol (Mosk); 2003; 37(6):1045-54. PubMed ID: 14714500
[TBL] [Abstract][Full Text] [Related]
37. Exploring the binding interaction of potent anticancer drug topotecan with human serum albumin: spectroscopic, calorimetric and fibrillation study.
Khan AY; Suresh Kumar G
J Biomol Struct Dyn; 2018 Jul; 36(9):2463-2473. PubMed ID: 28760107
[TBL] [Abstract][Full Text] [Related]
38. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
39. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
40. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
